Sasha is a co-founder and partner at Greybrook Capital and currently the CEO of Greybrook Securities Inc. where he shares responsibility for the firm’s private equity and real estate investment strategies. Under his leadership and on behalf of investors in over 30 countries, Greybrook’s portfolio has grown to include over 90 residential development projects representing over $20 billion worth of estimated completion value. Sasha is co-chair of Greybrook’s Investment Committee and Project Management Committees that are responsible for new acquisitions and actively managing all existing project partnerships.
As the former President of Greybrook Health, Sasha also played a key role in several portfolio acquisitions including MacuHealth, Bruder Healthcare and TearLab, as well as the launch of Greenbrook TMS (NASDAQ: GBNH; TSX: GTMS), a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. In 2020, he led the launch of Delos Canada, as well as Greybrook’s investment in Delos Living, LLC a global leader in the health and building sciences.
Sasha’s directorships include representation on the board’s of Greenbrook (NASDAQ: GTMS), Greyspring Apartments and Delos Canada and charitably on the boards of the Greybrook Foundation and the Blu Genes Foundation.